Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
País/Região como assunto
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Am J Trop Med Hyg ; 103(2): 756-759, 2020 08.
Artigo em Inglês | MEDLINE | ID: mdl-32394887

RESUMO

Clinical failure of primaquine (PQ) has been demonstrated in people with CYP450 2D6 genetic polymorphisms that result in reduced or no enzyme activity. The distribution of CYP2D6 genotypes and predicted phenotypes in the Cambodian population is not well described. Surveys in other Asian countries have shown an approximate 50% prevalence of the reduced activity CYP2D6 allele *10, which could translate into increased risk of PQ radical cure failure and repeated relapses, making interruption of transmission and malaria elimination difficult to achieve. We determined CYP2D6 genotypes from 96 volunteers from Oddor Meanchey Province, Cambodia, an area endemic for Plasmodium vivax. We found a 54.2% frequency of the *10 allele, but in approximately half of our subjects, it was paired with a normal activity allele, either *1 or *2. The prevalence of *5, a null allele, was 9.4%. Overall predicted phenotype percentages were normal metabolizers, 46%; intermediate metabolizers, 52%; and poor metabolizers, 1%.


Assuntos
Antimaláricos/uso terapêutico , Citocromo P-450 CYP2D6/genética , Malária Vivax/tratamento farmacológico , Primaquina/uso terapêutico , Artemisininas/uso terapêutico , Povo Asiático/genética , Camboja , Quimioterapia Combinada , Doenças Endêmicas , Frequência do Gene , Genótipo , Humanos , Variantes Farmacogenômicos , Fenótipo , Plasmodium vivax , Polimorfismo Genético , Quinolinas/uso terapêutico , Recidiva , Falha de Tratamento
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA